DCGI grants EUA to Hetero’s Biosimilar Version of Tocilizumab

This demonstrates our technical capabilities and commitment to bringing important therapeutics relevant to C-19 care


Last Updated on September 9, 2021 by The Health Master

India, Hyderabad: Hetero announced today that the Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India.

This authorization will enable the medical practitioners to use the generic drug Tocilizumab for the treatment of C-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Dr. B. Partha Saradhi Reddy, Chairman, Hetero Group said: “We are pleased with the approval of Hetero’s Tocilizumab (Tocira) in India.

This demonstrates our technical capabilities and commitment to bringing important therapeutics relevant to C-19 care.

This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the Government to ensure equitable distribution.”

Hetero’s TOCIRA (Tocilizumab) will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its strong distribution network across the country.

Hetero’s biologics arm ‘Hetero Biopharma’ will be manufacturing the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad, India.

Hetero’s Tocilizumab 400mg/20ml is the biosimilar version of Roche’s Actemra/RoActemra ®, and will be available from September end.







Aleor gets USFDA final approval for Metronidazole gel

Dr Reddy’s Labs gets USFDA nod for generic Librax capsules

Granules India gets Health Canada nod for drug for Arthritis pain

Sun Pharma gets exclusive right for Winlevi acne cream in US,…

Aurobindo Pharma gets USFDA nod for cancer treatment drug

USFDA approves drug for severe Itching in kidney disease patients

India has the best digital friendly regulatory system: DCGI

India and Pharmacy Education: Chapter: 6

No price regulation on these Medical Devices: Govt

USFDA updates norms to conduct Human studies

This is why young Indians more vulnerable to heart attacks: Doctors

Latest Notifications regarding Pharmaceuticals


Enter your email address:

Delivered by FeedBurner